- |||||||||| Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Nov 30, 2015 P4, N=40, Recruiting, Completed --> Active, not recruiting Trial primary completion date: Jun 2016 --> Nov 2016
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed: An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (clinicaltrials.gov) - Oct 20, 2015 P2, N=40, Active, not recruiting, N=48 --> 7 | Active, not recruiting --> Terminated; Due to cranial nerve palsies observed Recruiting --> Active, not recruiting
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Sep 25, 2015 P2, N=35, Completed, Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Completed
- |||||||||| Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Trial completion: Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication (clinicaltrials.gov) - Aug 24, 2015 P1, N=30, Completed, Initiation date: Jul 2015 --> Oct 2015 Active, not recruiting --> Completed
- |||||||||| Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Phase classification, Enrollment change: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Aug 11, 2015 P2, N=18, Recruiting, Active, not recruiting --> Completed Phase classification: P4 --> P2 | N=60 --> 18
- |||||||||| birinapant (IGM-9427) / IGM Biosciences
Trial primary completion date, Combination therapy: Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) - Jun 18, 2015 P1/2, N=45, Active, not recruiting, Recruiting --> Active, not recruiting | N=250 --> 106 Trial primary completion date: May 2015 --> Aug 2015
- |||||||||| birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
Enrollment closed, Trial primary completion date, Combination therapy: Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) - Jun 1, 2015 P1, N=40, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Aug 2015
- |||||||||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed, HEOR: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (clinicaltrials.gov) - May 8, 2015 P4, N=314, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Enrollment closed: Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication (clinicaltrials.gov) - Mar 24, 2015 P1, N=30, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
|